348184-48-5

Upstream product

• 32150-92-8 (R)-2-(1,3-dioxoisoindolin-2-yl)-3-phenylpropanoyl chloride 
• 3588-64-5 (R)-2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-phenylpropionic acid 
• 673-06-3 D-(R)-phenylalanine 
• 866395-52-0 N-(1-benzyl-3-hydroxy-propyl)-2-hydroxymethyl-benzamide 
• 866395-50-8 methyl (R)-3-phthalimido-4-phenylbutyrate 
• 866395-47-3 (R)-1-diazo-3-phthalimido-4-phenylbutan-2-one 
• 501-53-1 benzyl chloroformate 
• 228422-44-4 (R)-1-benzyl-3-hydroxypropylamine 

Downstream Products

• 866395-33-7 (2S,9R,12S,19R)-2,6-cyclo-12,16-cyclo-6,10,16-triaza-9-benzyl-19-(benzyloxycarbonylamino)-20-phenyl-11-oxoeicosanoic acid methyl ester 
• 866395-30-4 (2S,9R,12S)-2,6-cyclo-12,16-cyclo-6,10,16-triaza-9-benzyl-19-(benzyloxycarbonylamino)-11-oxononadecanoic acid methyl ester 
• 866395-27-9 (2S,9R)-2,6-cyclo-6-aza-9-(benzyloxycarbonylamino)-10-phenyldecanoic acid methyl ester 
• 866395-42-8 (S)-1-((R)-3-Benzyloxycarbonylamino-4-phenyl-butyl)-pyrrolidine-2-carboxylic acid 
• 866395-24-6 (S)-1-mesyloxy-N-(benzyloxycarbonyl)-3-amino-4-phenylbutane 

Relevant academic research and scientific papers

Structure-driven design and synthesis of chiral dioxocyclam derivatives

Based on an analysis of previously reported structures and a potential geometry fit with substrates, a new family of chiral dioxocyclam derivatives have been designed. The synthesis of those ligands was accomplished starting from l-proline and α-d-amino acids (converted to β-amino acids) with a key step of macrocyclization reaction of amino esters. All ligands were converted into neutral copper(II) complexes (amide groups underwent deprotonation of upon treatment of ligands with copper(II) acetate). The complexes exhibit the desired shape of their active surfaces, as proved by X-ray analysis.

Fused purine derivatives

A condensed purine derivative represented by Formula (I): wherein X—Y—Z represents R1N—C═O or N═C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R1aN—C═O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR7R8, —CO2H, a lower alkoxycarbonyl group, —COHal, —CONR9R10 or —CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.